lung cancer

Patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer Benefit from Selpercatinib: LIBRETTO-432 Early Results An interview with: Jonathan W. Goldman MD, Director of Clinical Trials i

AI “Pathomics Platform” Selects Immunotherapy, Predicts Outcome for Patients with Metastatic Non-Small Cell Lung Cancer  An interview with: Rukhmini Bandyopadhyay MD, Postdoctoral Fellow, The Universi

Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer An interview with: Jonathan Wesley Riess MD, Professor of Medic

Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy

Victor E Velculescu MD PhD

PARIS, France—the open-label international phase three randomized IPSOS study reported at the 2022 European Society for Medical Oncology congress that patients with non-small cell lung cancer who were

UK & NETHERLANDS—Following the the AJO Podcast interview with Professor Harry de Koning MD PhD, from the Erasmus University in Rotterdam, who discussed his research published in the New England Jo

Second Study Confirms Lung Cancer CT Screening Cuts Deaths NETHERLANDS—Erasmus University Medical Center, Rotterdam—Research published in the New England Journal of Medicine has confirmed the viabilit

MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK ge

MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSC

CHICAGO, IL—Patients whose non-small cell lung cancers (NSCLC) expressed more than one per cent of the programmed death ligand-1 (PD-L1) tumor proportion score (TPS) lived longer when treated with the

Audio Journal of Oncology, January 2, 2017 COPENHAGEN—Patients with metastatic non-small cell lung cancers (NSCLC) expressing the programmed cell-death ligand 1 (PD-L1) protein responded better to ini

The Audio Journal of Oncology Reporting from the 2016 Congress of the European Society of Medical Oncology COPENHAGEN—The anti-PD-L1 (programmed cell death ligand-1) immunotherapy agent atezolizumab e

COPENAGEN—Adding the PD-1 (programmed cell death protein 1) antibody pembrolizumab to standard first-line chemotherapy with carboplatin and pemetrexed for previously-untreated patients with advanced n

COPENHAGEN—In a phase I study reported at the 2016 congress of the European Society for Medical Oncology (ESMO) six out of 15 patients with resectable early non-small cell lung cancer had “major

Data showing that whole brain radiotherapy should not be used in patients whose non-small cell lung cancer has metastasized to the brain were reported at the European Respiratory Society 2016 congress

Christian Manegold Roy Herbst More Support for Bevacizumab in Advanced Lung Cancer REFERENCE: Abstract LBA7514, ASCO Annual Meeting Chicago June 1-5, 2007 CHRISTIAN MANEGOLD, Heidelberg University, Ma

PETER HARPER, Guy’s Hospital, London REFERENCE: “Management of Tumour and Treatment Related Symptoms” section, Perspectives in Lung Cancer, Seville Bisphosphonates may be more suited

DAVID JABLONS, University of California, San Francisco REFERENCE: Keynote Lecture, Perspectives in Lung Cancer Conference, 2-3 March 2007, Seville, Spain Cell signalling using the Wnt pathway may hold